


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF NEW DRUG APPLICATION FOR ROPIVACAINE
HYDROCHLORIDE SUSTAINED-RELEASE SOLUTION

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a new drug application for ropivacaine hydrochloride sustained-release solution, a national Category 2.2 new drug independently developed by Beijing Tide Pharmaceutical Co., Ltd. (“**Beijing Tide**”, a subsidiary of the Group), has been submitted to and accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration, for postoperative long-acting analgesia in adults. This drug is the world’s first novel long-acting ropivacaine analgesic administered via intra-incisional instillation.

Ropivacaine hydrochloride is the first pure levorotatory long-acting amide-type local anesthetic. At high doses, it can produce surgical anesthesia, while at low doses, it can provide the effect of sensory blockade (analgesia). It blocks axonal sodium influx and inhibits neuronal membrane depolarization, thereby interrupting action potential propagation and blocking pain signal transmission. Compared with bupivacaine, a drug in the same class, ropivacaine hydrochloride offers clinical advantages of lower cardiotoxicity and a more pronounced separation of motor and sensory blockade.

Ropivacaine hydrochloride sustained-release solution is a novel long-acting non-opioid analgesic, developed using a proprietary lipid-based targeted injection technology platform. The drug features an innovative intra-incisional instillation administration, topically applied before wound closure. The straightforward application procedure helps shorten healthcare professionals’ operation time and significantly improves clinical convenience. Leveraging its advanced formulation, the drug undergoes a phase transition upon contact with tissue fluid at the administration site, forming a drug reservoir that enables sustained drug release for up to 72 hours. Compared with conventional multi-site infiltration administration, this drug significantly reduces systemic exposure, with a superior safety profile.

Results from two pivotal Phase III registrational clinical trials showed that in unilateral hip replacement (somatic pain model) and abdominal surgery (somatic/visceral mixed pain model), a single administration of ropivacaine hydrochloride sustained-release solution provided sustained analgesia for up to 72 hours, significantly reducing the dose and frequency of rescue analgesic use. The analgesic efficacy was significantly superior to that of the active control, and the overall safety profile was good. Pharmacokinetic studies indicate that this drug exhibits sustained-release characteristics, including delayed absorption, lower peak serum concentrations, a longer plateau phase at peak concentration, lower systemic exposure, and a gradual elimination process, further confirming its clinical value in prolonging analgesic duration, enhancing safety, and improving compliance.

The acceptance of the marketing application for ropivacaine hydrochloride sustained-release solution will further enrich the Group's product portfolio in the area of long-acting analgesia and enhance its postoperative pain management franchise. This drug offers a differentiated and complementary alternative to the Group's existing marketed products and can be used in combination in clinical settings, helping to optimize postoperative pain management regimens and further consolidate the Group's competitiveness and market position in the analgesia space.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 3 July 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.